Avaii Wealth Management LLC Grows Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Avaii Wealth Management LLC grew its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 4.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,393 shares of the biopharmaceutical company’s stock after purchasing an additional 1,409 shares during the quarter. Avaii Wealth Management LLC’s holdings in TG Therapeutics were worth $915,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in TGTX. NBC Securities Inc. increased its holdings in TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 485 shares in the last quarter. Blue Trust Inc. increased its stake in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares in the last quarter. ORG Wealth Partners LLC acquired a new position in TG Therapeutics in the 3rd quarter worth about $53,000. Values First Advisors Inc. purchased a new position in TG Therapeutics during the third quarter worth approximately $58,000. Finally, GAMMA Investing LLC grew its holdings in TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,171 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TGTX has been the subject of several research analyst reports. TD Cowen started coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price for the company. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Wednesday, January 15th. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Finally, The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

Insider Activity at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,358 shares of company stock valued at $781,497. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $31.26 on Friday. The firm has a 50-day simple moving average of $31.57 and a 200-day simple moving average of $26.16. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $4.87 billion, a price-to-earnings ratio of -312.57 and a beta of 2.24. TG Therapeutics, Inc. has a 52 week low of $12.84 and a 52 week high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same period in the prior year, the company posted $0.73 EPS. The firm’s revenue was down 49.4% on a year-over-year basis. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.